A Cross-sectional Study on Prevalence of Vitamin B12 Deficiency and Peripheral Neuropathy between Metformin Users and Non Users in Participants with Type 2 Diabetes Mellitus
Abstract
Introduction: Metformin is a first line drug for treatment of Type 2 Diabetes Mellitus (T2DM) which acts by decreasing insulin resistance. Metformin use can lead to vitamin B12 deficiency. Aim: To evaluate the difference in proportion of vitamin B12 deficiency and clinical neuropathy between metformin users and metformin non users in patients with T2DM. Materials and Methods: This cross-sectional study was conducted at Department of General Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India, from Jul 2015 to June 2017. Hundred patients with T2DM were recruited in the study, and divided into two groups i.e., T2DM patients on metformin (n=50) and without metformin (n=50). One group were patients of diabetes who were on metformin for more than three years, and the other group were those who had not taken metformin in last three months. All participants were evaluated with serum vitamin B12. Toronto Clinical Neuropathy (TCN) score was used to diagnose peripheral neuropathy. Multivariable logistic regression was done to look for association between metformin use and vitamin B12 deficiency and peripheral neuropathy separately. Results: Between the metformin users and non metformin user group, the proportion of males (72% vs 66%, p-value=0.66) and the age (56.02±9.19 vs 56.16±8.33 years, p-value=0.93) were similar in both groups. Median duration of diabetes among metformin users was 10.18 years (IQR=6.68-16.68 year) and non metformin…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 50 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.